Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Clayton I. Duncan
AddedMar 31, 2024
UpdatedMay 31, 2026
Clayton I. Duncan

Clayton I. Duncan

CEO, Accele Venture Partners

CrunchbaseLinkedIn

Clayton I. Duncan's Career

Accele Venture Partners
Accele Venture Partners

Oklahoma City, OK, US

CEO· C-Suite · Management
Valanbio Therapeutics
Valanbio Therapeutics

Raleigh, NC, US

CEO· C-Suite · Management
Pamlico Biopharma
Pamlico Biopharma

Oklahoma City, OK, US

Board Member· Board
Otologic Pharmaceutics
Otologic Pharmaceutics

Oklahoma City, OK, US

CEO· C-Suite · Management

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Clayton I. Duncan's Career

Accele Venture Partners
Accele Venture Partners
Investment Firm62012Oklahoma City, OK, US
CEO· C-Suite · Management

Similar to Accele Venture Partners

Advent Venture PartnersAdvent Venture PartnersLondon, Greater London, GBest. 2002Advent Venture PartnersLondon, Greater London, GB · est. 2002

Advent Venture Partners: A UK-based venture capital firm investing in life sciences and technology.

34
LifeSci Venture PartnersLifeSci Venture PartnersNew York City, NY, USest. 2017LifeSci Venture PartnersNew York City, NY, US · est. 2017

LifeSci Venture Partners, formed in 2017, is an early-stage investment firm in life sciences and healthcare.

5
Mediphase Venture PartnersMediphase Venture PartnersNewton, MA, USest. 1999Mediphase Venture PartnersNewton, MA, US · est. 1999

Mediphase Venture Partners: A US-based venture capital firm specializing in healthcare and life sciences.

7
Impact Venture PartnersImpact Venture PartnersNew York City, NY, USest. 1999Impact Venture PartnersNew York City, NY, US · est. 1999

Venture capital firm, Impact Venture Partners LP, specializes in IT investments in the US.

6
Valanbio Therapeutics
Valanbio Therapeutics
$421k302015Raleigh, NC, US
CEO· C-Suite · Management

Leadership at Valanbio Therapeutics

Moise KhayrallahMoise KhayrallahBoard Member
Pamlico Biopharma
Pamlico Biopharma
$2.2M62011Oklahoma City, OK, US
Board Member· Board

Leadership at Pamlico Biopharma

Mark H N CorriganMark H N CorriganBoard Member

Similar to Pamlico Biopharma

IdbiologicsIdbiologicsNashville, TN, USAntibodies, Therapeuticsest. 2017IdbiologicsNashville, TN, US · est. 2017

IDBiologics: Pioneering infectious disease treatment through rapid discovery and optimization of human monoclonal antibodies.

$4.8M7
BioClonetics ImmunotherapeuticsBioClonetics ImmunotherapeuticsRockwall, TX, USAntibodies, Biopharmaceuticalsest. 2009BioClonetics ImmunotherapeuticsRockwall, TX, US · est. 2009

BioClonetics: A biotech firm developing and producing monoclonal antibodies to combat infectious diseases.

Public · $255.6k6
MicrobplexMicrobplexAtlanta, GA, USDiagnostic Platformsest. 2011MicrobplexAtlanta, GA, US · est. 2011

MicroBPlex develops diagnostic platforms using innovative antibodies to identify acute microbial infections.

$248.7k6
Plasmonic DiagnosticsPlasmonic DiagnosticsColumbia, MO, USDiagnostics, Testingest. 2015Plasmonic DiagnosticsColumbia, MO, US · est. 2015

Missouri-based Plasmonic Diagnostics offers precise solutions for detecting infectious, STDs, and cancer.

$224.9k1
Otologic Pharmaceutics
Otologic Pharmaceutics
$4.1M82009Oklahoma City, OK, US
CEO· C-Suite · Management

Leadership at Otologic Pharmaceutics

Dave KarlmanDave KarlmanCo-Founder
Robert FloydRobert FloydCo-Founder
Richard KopkeRichard KopkeCo-Founder

Similar to Otologic Pharmaceutics

OtoKineticsOtoKineticsSalt Lake City, UT, USMedical Devicesest. 2009OtoKineticsSalt Lake City, UT, US · est. 2009

OtoKinetics: Innovating implants for severe hearing loss.

$490k5
Pharmaceutics InternationalPharmaceutics InternationalHunt Valley, MD, USDrug Developmentest. 2016Pharmaceutics InternationalHunt Valley, MD, US · est. 2016

Founded in 1994, Pharmaceutics International, Inc. is a contract development and manufacturing firm specializing in biological research.

$148M375
OptinoseOptinoseYardley, PA, USPharmaceuticalsest. 2010OptinoseYardley, PA, US · est. 2010

Optinose, Inc.: A specialty pharmaceutical firm innovating ENT and allergy treatments.

Public141
Otologic TechnologiesOtologic TechnologiesMadison, WI, USAI Toolsest. 2019Otologic TechnologiesMadison, WI, US · est. 2019

Otologic Technologies, an AI health tech startup, enhances ear ailment diagnosis accuracy with innovative tools.

$705k8

People Similar to Clayton I. Duncan

Lau Eng BoonLau Eng BoonBoard Member · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakNugroho HerucahyonoNugroho HerucahyonoCo-Founder · BukalapakAchmad ZakyAchmad ZakyCo-Founder · BukalapakWillix HalimWillix HalimCEO · BukalapakChi-hyung SongChi-hyung SongBoard Member · DunamuHaeil YiHaeil YiCo-Founder · DunamuKent NovakKent NovakCEO · ValencellDavid BerryDavid BerryCo-Founder · Seres TherapeuticsDave JohnsonDave JohnsonFounder & CEO · Solve TherapeuticsHolger von DanielsHolger von DanielsFounder · valanticAnthony GadientAnthony GadientBoard Member · TrackStreetDrew ReidDrew ReidFounder · Maple Materials